ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HYDROCHLORIDE and BLINDNESS TRANSIENT

Overview

BLINDNESS TRANSIENT is the #14 most commonly reported adverse reaction for ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HYDROCHLORIDE, manufactured by Bayer HealthCare LLC.. There are 1 FDA adverse event reports linking ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HYDROCHLORIDE to BLINDNESS TRANSIENT. This represents approximately 1.5% of all 68 adverse event reports for this drug.

Patients taking ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HYDROCHLORIDE who experience blindness transient should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

BLINDNESS TRANSIENT is a less commonly reported adverse event for ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.

Other Side Effects of ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HYDROCHLORIDE

In addition to blindness transient, the following adverse reactions have been reported for ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HYDROCHLORIDE:

• CHOKING — 12 reports
• FOREIGN BODY IN THROAT — 8 reports
• VOMITING — 4 reports
• DYSPNOEA — 3 reports
• OROPHARYNGEAL PAIN — 3 reports
• PRODUCT USE COMPLAINT — 3 reports
• DIZZINESS — 2 reports
• FOREIGN BODY IN RESPIRATORY TRACT — 2 reports
• NAUSEA — 2 reports
• RETCHING — 2 reports

Other Drugs Associated with BLINDNESS TRANSIENT

The following drugs have also been linked to blindness transient in FDA adverse event reports:

Does ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HYDROCHLORIDE cause BLINDNESS TRANSIENT?

BLINDNESS TRANSIENT has been reported as an adverse event in 1 FDA reports for ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is BLINDNESS TRANSIENT with ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HYDROCHLORIDE?

BLINDNESS TRANSIENT accounts for approximately 1.5% of all adverse event reports for ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HYDROCHLORIDE, making it a notable side effect.

What should I do if I experience BLINDNESS TRANSIENT while taking ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HYDROCHLORIDE?

If you experience blindness transient while taking ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, PHENYLEPHRINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages